Fulcrum CEO Resigns
January 4, 2023
Fulcrum Therapeutics announced its CEO, Bryan Stuart, resigned and the company named Robert Gould, who headed the company when it launched in 2016, as its interim president and CEO..
The company, which is developing treatments for the blood disorder sickle cell disease (SCD) and the neuromuscular disorder facioscapulohumeral muscular dystrophy (FSHD), came as Fulcrum readies to make a presentation at the critical annual JPMorgan Healthcare Conference.
“We are entering 2023 with a tremendous amount of momentum and expect it to be a productive year for our two clinical programs: FTX-6058 for SCD, and losmapimod for FSHD,” said Gould.
He called FTX-6058 a potential “best-in-class” oral HbF inducer candidate that could address critical gaps in the SCD treatment landscape. He also noted that the phase 3 REACH trial with losmapimod, a potential first-to-market therapy in FSHD, is expected to complete enrollment in the second half of the year.
Prior to joining Fulcrum in 2016, Gould served as president and CEO of Epizyme from 2010 to 2015. Before that, he served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Gould spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, he was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas.
Gould holds a bachelor’s degree from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.
Sign up for updates straight to your inbox.